Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't get this business of the slide being changed. It was on slide 9 last night. just look at the sticky from Whooops that was posted last night.
I don't know the answer to your question but it got me thinking - how will the physical plant relate to Kard? Also, PolyMedix had 20 some employees at the peak. Can Kard handle the new workload or need to hire? Or, will this signal a new chapter where lab research is done outside the Kard framework? Kard has been good for us but with all these compounds it may be pushing the limit of what Kard can accommodate. It will be interesting to see how the growing pains play out.
Good point Sox. They may have thought CTIX looks like a winner and the value would skyrocket. Much like we think.
The Stalking Horse business is interesting. CTIX was chosen by the bankrupt company to make the first bid to avoid lowball offers. I guess they were the only bidder. I wonder what inspired PolyMedix to pick CTIX as the Stalking Horse?
Definition of 'Stalking-Horse Bid'
An initial bid on a bankrupt company's assets from an interested buyer chosen by the bankrupt company. From a pool of bidders, the bankrupt company chooses the stalking horse to make the first bid.
Investopedia Says
Investopedia explains 'Stalking-Horse Bid'
This method allows the distressed company to avoid low bids on its assets. Once the stalking horse has made its bid, other potential buyers may submit competing bids for the bankrupt company's assets. In essence, the stalking horse sets the bar so that other bidders can't low-ball the purchase price.
That is a steal! And don't be sad Whooops. There is only so much two guys can do!!!
Thanks for posting this. In reading it I see the bacterial drug mimics the mechanism of the immune system. This sort of dovetails with K reactivating P53 in that it isn't just the old poison approach that so many therapeutics use. Instead it is restore or improve upon what the body tries to do in dealing with an affront. This approach seems logical and yet maybe isn't used enough.
As to why someone else, especially the competitor they bested, didn't buy it - who knows? But I'll say that CTIX has really impressed me with this move. They keep their ear to the ground and seem to be able to do so much with so few people.
The funny thing to me is I actually had looked at this stock as a purchase awhile back. I was pretty impressed with what I saw. Now I got it the easy way, and avoided a lot of financial pain in the process. Sometimes you just get lucky.
It is news. And Leo may expand a bit on what we see on the slide. You can't get to second base if you don't make it to first and I think the news is about as good as one can expect at such a low dosage. The fact that the hematology markers are clean is just excellent, reinforcing the prospects of future dosing increases.
I'm ecstatic. I have been catching up and every time I think I have there are another 5 posts! I've ghot enough new info here to hold me for a week of reading. Thanks to the DD posters - we have quite a group on this board.
There may be a premium over the .04 share price if there were other bidders but probably not a lot. I think bankruptcy cancels any debt to the acquirer except to the extent that the purchase price is doled out. Can't wait to hear the details on the acquisition.
It is very interesting. You can freeze it on the screen too. I did it by increasing the mag to 400% and then hit refresh and then return it to 150%. The screen stays on the first page.
Hmmm...compounds for cures.
I think this is how we will all feel very soon.
http://www.liveleak.com/view?i=4f4_1354006741
Nobody bit here when I put the words money maker here instead of market maker. I was hoping some one would so I could go on a little rant about that. I'll save it for another time.
Usually the vocal ones are feeling the squeeze. A successful short is just smiling all the way to the bank with no need to make a lot of noise.
And on good volume.
Yes a different definition than what I am talking about. You are describing flippers or traders - those who see a short term opportunity to benefit from some kind of catalyst. A true short has bet the stock price will go down by essentially agreeing to buy the share at a lower price. Their profit comes from the difference between the higher price when they placed the trade and the lower price when they cash out. By the way the worst kind of short is the money maker - they can do naked shorts, which is quite debatable as to whether it should even be legal. The securities industry has fought hard to keep this in place arguing it is needed for "an orderly market."
Gov that is why I think this is such a bad stock for a true short. Yes it bumps around by a few pennies but IMO the beta on this stock does not make it an attractive opportunity for those who like to go short.
Just for the fun of it I went and looked up the short interest on CTIX at short squeeze.com - see below:
http://shortsqueeze.com/?symbol=CTIX&submit=Short+Quote%99
It says 138,600 shares are short or .7 days to cover. Not much conviction in the short community for going up against this stock. I have owned stock where 40% of the float was short - now that is a battle of sentiment. What we are seeing here are a few outliers who IMO don't know much about selecting a short or they would have placed their bet elsewhere.
I don't think so. Longs here are very informed and feel we have hold of something quite special. Some newby shows up and states something that is unverifiable isn't going to gain much traction with this group. And we are the ones that would have to sell given the float. This is not a good stock for a rumor monger or a short.
The Holy Grail sounds pretty good.
Thanks for that reference to the patent Gratefullife. I had read through that once awhile ago but hadn't really made the connection to where that might lead outside of cancer. I mean what can you say? Simply mind boggling to think where this might lead.
Okay this is going to be a little out there but look at it as a chance to educate me if I am totally off base. Also, since many are having a hard time waiting for the R&R conference you may want to skip this because you will wait a really long time if anything I am about to lay out is even possible.
Earlier today I asked dmattingly if a question to Dr. Menon is appropriate at the R&R conference. I did not get a response but have thought about my question some more and decided it probably isn't. It seems too speculative and too broad of a question to me. But I will throw it out to the board to see what others think. As noretreat said the other day the amusing speculation is what makes the board worth reading. So here goes:
p53 is a guardian of the genome for much more than oncologic disease. Loss of p53 function is implicated in cardiovascular, metabolic and neurodegenerative disease. Has Cellceutix investigated or considered investigating whether the many permutations noted in the patent for Kevetrin might have applicability to non-oncologic disease? p53 regulates many genes that "underlie all these biologic events." As just one example, there is research indicating Alzheimers may be linked to disruption of HIPK2 activation of apoptosis by phosphorlation at SER 46 (see linked article).
I started investigating this a few days ago because of another stock I own that is involved with neurodegenerative diseases. In digging into it I started to see mention of p53 activation being a possible key and went from there. Leo has said that as far as he knows Cellceutix is the only drug currently out there that activates p53. I know Dr. M has his hands full but is it possible that the central tenet of p53 activation could lead to a wide range of applications outside of oncology depending on whether the base molecule in Kevetrin can be tweaked to the specific pathology. A wild thought.
Kevetrin induces phosphorylation at SER15, but apoptosis is also induced at SER6,Ser9, Ser20, Ser37 and Ser46 that I have read about. I also have seen the following quote " Alzheimer's disese, Parkinson's disease, cystic fibrosis, prion diseases and many types of cancer are considered to be protein conformation diseases." So in some sense the mechanism of these diseases has a commonality.
It got me thinking about the mystery compounds in the CTIX lineup too. What are those compounds? Probably way too much to expect from our little company but it is kind of intriguing. Maybe some of our posters with knowledge on these matters could weigh in on whether this idea of non-oncologic application is even a remote possibility. If (admittedly a big if) this were the case then...I wouldn't even know how to finish the sentence. I have included a link to the most readable of several articles I have read recently. One sentence from the linked article: "In the fourth decadeof p53 investigation the research community hopes to be able to get new drugs to affect p53 function to treat not only cancer but also important neurological conditions, such as AD."
The article is about applicability to Alzheimers.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984604
Pfizer and Celgene. Now were talking!
Confidentiality Disclosure Agreement
DMat - Is it appropriate to ask a question that is more properly directed to Dr.Menon? Will he be there? I have one if so.
Does anyone know which company has signed a CDA with CTIX besides Pfizer? The article mentions two CDAs.
It is so encouraging to see the overall trend in this type of cancer and others. There is a retinoblastoma case I remember that haunts me to this day. Back in the 1970s I got my first position in health care in a technical position in a University ophthalmology department. A little girl was brought to the department by the government of India in a last ditch effort to see if there was anything that could be done for the retinoblastoma in her eye. The case had the Indian people so upset the government stepped in to fly her to a handful of leading eye departments around the world while no doubt knowing nothing could be done. The case was one of wrong side surgery - in India the good eye had been removed leaving the girl with the cancerous eye. Just devastating. Imagine if an efficacious Kevetrin had been available then and all you had to do was take a pill.
I have lurked around here a bit but decided to bite the bullet and subscribed today. Recognize a few of you from another board where we share a common interest. Funny how people gravitate to the same kind of risk/reward situations so maybe it is not surprising I recognize a few names.
Just read the new newsletter. I will be liquidating some old positions come Tuesday to establish a starting position with one or two of these.
Good luck to everyone!
I sold another position to grab 5k today even though I finally reached my target a few days ago. I couldn't resist!
noretreat, A BB squeeze on this stock has often resulted in upside moves, especially when bouncing along the lower BB. No indications of being overbought so I think we are okay.
If they can do this for mice...
The mice were followed for 180 days. Endpoints were skin appearance, histological observations, PRINS expression, and blood levels of IL-20.
Well said. A legacy is a hard thing to buy off if that is really the way they feel. I hope it is. When a product is taken to maturity it is a different valuation model as potential slowly turns into reality. I think there is deep value here that will pay off for investors and those afflicted by the conditions involved.
I finished off my purchases today as I now have the position I originally sought. It took 3 months as I had to close out other trades. I feel the market stability was good for my purchases during that time but now I am ready for the catalysts to start!
I had to laugh Pete. Your wife and mine have a lot in common.
But risk on/off has another player and that is the CTIX team. Are L and M going to ride this out or will they be amenable to a nice offer that removes upstream risk?
Double, I think I get the gist of what you are saying. So,
"Does this seem extraordinarily high to others?" Maybe so, but L and M control more shares, options,warrants than most insiders. So it makes sense.
"Is it guaranteed they will exercise the warrants etc...?" If your premise is simply control they would not need to exercise all of them to control the company with what is in play now, especially with B shares. Will they? There is more at play than control as in a lot of $. So I assume they will.
"Are you missing something?" Maybe another way to answer that question is to assume all the 150 million are exercised before the buyout offer ever occurs. At a 5B market cap, the share price is about $33. Now you might feel better because you will get the 100% you wanted or another $33, which gets you to the same $67. So maybe you do not feel better. So given the figures you used I don't think you are missing anything.
That said, it's a pretty nice return isn't it? At that point I will not be worrying about whether I only have $17 upside on the buyout. I will be worrying about whether my 2nd home will be in Hawaii or Tahiti.
At least we have a pretty color as we watch the paint dry.
I am with you on this Pete. Loan sent me a nice response to my request explaining the A & B share voting structure. Anyone who helps me better understand my investment is okay by me.
Loan, I am interested in your info regarding the features you mentioned. I cannot PM you. Can you send me a message?
Thanks.
A couple of comments about my previous post. The name of the book is actually "The Emperor of all Maladies - A Biography of Cancer." It won the Pulitzer Prize. Prominent mention in the book of the work of Sidney Farber. It is quite interesting to look at the accomplishments of the shining lights of medicine, and how they came to be that. No one would have predicted that for Farber - a pediatric pathologist, not a leukemia specialist. And now to think DF is named after him. Goes to show what can be accomplished by those of who think a little outside the box. Like the post from gov on that nurse Kenny and her unorthodox views.
How I discovered CTIX:
I have been enjoying the accounts as to how posters made their way to a position in CTIX so thought I would join in.
About 2 years ago I was out on my Kindle trying to find a book to read when I ran across some great reviews for a book titled "The Emperor of All Maladies : A History of Cancer" by Mukurjee. Seems an odd choice for casual reading but I worked in Hopital Admin of University based academic medical centers for 35 years and had rubbed shoulders with a number of Oncologists. So it was not odd for me. Anyway, Mukerjee's book was all it was hyped to be - just a fascinating read into all the failures and triumphs of this long battle with an intractable foe. Late in the book I read about P53 and found it intriguing.
A couple years later someone on a different chat board mentions CTIX as a stock he or she likes. I put it on my list to check out when I had the time. When I did there was the reference to P53. I continued my DD and became more intrigued - especially with Prurisol in the picture. But more than anything it was the P53 pathway that sold me on the stock. So I took a fairly large position over the past few months.
I got clobbered on this today. A lot of manipulation on both sides. There was the SA article on the short side. But Aegis was just as sleazy with their buy recommendation when the price fell. Aegis is the MM for NVIV and I don't care much for their veiled attempt to manipulate things even if it would have helped me. I just don't like the MM making BUY or SELL recommendations even if it is supposedly a different branch of the same company. Not that it did any good. The shorts had their day anyway as people were already nervous from the news about Frank as the stock started to recover a little before the big plunge. Then the SA article and no BUY recommendation could offset that. Still sleazy of Aegis though - there ought to be a law against that IMO. MMs already have too much power to manipulate prices without issuing recommendations. Hope we get some of this back Monday. GLTA.
WHO KNEW WHAT WHEN?
Progressive makes an excellent point. Based on the email MoDog has made an assumption that the communication will be a PR. The email does not say that. We may get one as there is past communication that may occur. But there is a possibility we will not as well. Likewise, MoDog may get some non-material answers to his questions this weekend and no PR. It could go either way. Leo did not specifically say there will be a PR this weekend.